Myriad Genetics Inc (NAS:MYGN)
$ 24.225 -1.735 (-6.68%) Market Cap: 2.20 Bil Enterprise Value: 2.40 Bil PE Ratio: 0 PB Ratio: 2.97 GF Score: 79/100

Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 12:30AM GMT
Release Date Price: $17.32 (+3.53%)
Unidentified Analyst

Good afternoon, everyone. My name is [Martina Sarowitz]. I'm from the Growth Life Science Tools and Diagnostics team, part of Julia Qin's team. So it's my pleasure to introduce our next company, Myriad Genetics. Just as a reminder, following the presentation, we will have a Q&A session. (Operator Instructions) And with that, I will turn it over to Paul.

Paul J. Diaz
Myriad Genetics, Inc. - CEO, President & Director

Great. Thank you, and thank the JPMorgan team for inviting us today. Obviously, it's great to be in person with everyone, and I want to thank everyone in our audience today and those online. I understand there may not be any Georgia fans in the crowd here, but thank you for coming today.

We're excited to give you an update and tell you about our plans for the future. First, I will remind you that we'll be making certain forward-looking statements and that you can find more information about us and our GAAP reconciliations on our website.

With that, it's been a busy couple of years. We've made a tremendous

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot